Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David McDonnell

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Neuropsychiatric Disease and Treatment|September 16, 2021
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I DisorderLeslie Citrome, Christine Graham, Adam Simmons, et al.
Schizophrenia Bulletin|October 28, 2022
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 StudyChristoph U Correll, Evan Stein, Christine Graham, et al.
BMC Psychiatry|February 15, 2022
Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorderMichael J Doane, Leona Bessonova, Haley S Friedler, et al.
The Journal of Clinical Psychiatry|March 12, 2020
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical TrialMary F Brunette, Christoph U Correll, Stephanie S O'Malley, et al.
The American Journal of Psychiatry|August 15, 2020
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 StudyChristoph U Correll, John W Newcomer, Bernard Silverman, et al.
Schizophrenia Research|May 20, 2021
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extensionRené S Kahn, Bernard L Silverman, Lauren DiPetrillo, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 10, 2021
Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteersFrederico G S Toledo, William F Martin, Linda Morrow, et al.
Neuropsychiatric Disease and Treatment|March 20, 2025
Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of SchizophreniaLeslie Citrome, Christoph U Correll, Andrew J Cutler, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Neuropsychiatric Disease and Treatment|September 16, 2021
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I DisorderLeslie Citrome, Christine Graham, Adam Simmons, et al.
Schizophrenia Bulletin|October 28, 2022
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 StudyChristoph U Correll, Evan Stein, Christine Graham, et al.
BMC Psychiatry|February 15, 2022
Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorderMichael J Doane, Leona Bessonova, Haley S Friedler, et al.
The Journal of Clinical Psychiatry|March 12, 2020
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical TrialMary F Brunette, Christoph U Correll, Stephanie S O'Malley, et al.
The American Journal of Psychiatry|August 15, 2020
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 StudyChristoph U Correll, John W Newcomer, Bernard Silverman, et al.
Schizophrenia Research|May 20, 2021
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extensionRené S Kahn, Bernard L Silverman, Lauren DiPetrillo, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 10, 2021
Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteersFrederico G S Toledo, William F Martin, Linda Morrow, et al.
Neuropsychiatric Disease and Treatment|March 20, 2025
Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of SchizophreniaLeslie Citrome, Christoph U Correll, Andrew J Cutler, et al.
Pageof 4